News

This review of the latest dermatologic studies includes a new instrument to measure QoL in pediatric alopecia, BTX-A in patients with recessive dystrophic epidermolysis bullosa, eosinophilic pustular folliculitis in children, and more.

However, over half of the patients reported experiencing psychological symptoms such as mood changes and depression during treatment.

Citius Oncology’s IL-2 receptor–directed fusion protein offers rapid responses and pruritus improvement for relapsed or refractory stage I–III CTCL.

Participants agreed that HS is rarely controlled with monotherapy and often requires coordinated multimodal care.

Support vital dermatology organizations this Giving Tuesday and beyond to enhance patient care, drive research, and foster community.

Patrick Burnett, MD, PhD, of Arcutis, explores new treatments for vitiligo and hidradenitis suppurativa, while advancing systemic biologics for atopic dermatitis by 2026.

Mondana Ghias, MD, FAAD, offers strategies for dermatologists in managing skin reactions from lung cancer treatments to enhance patient care and quality of life.

While individual fatty acids in tallow have known biological effects, their combined impact in whole tallow remains uncertain.

Arcutis is advancing pediatric dermatology with innovative, steroid-sparing treatments for atopic dermatitis and plaque psoriasis, enhancing care for young patients.

Nayan Patel, PharmD, is revolutionizing skin rejuvenation with advanced delivery technology of GHK-Cu for youthful vitality.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about LNK01004's phase 2 AD results, INF904's efficacy in HS and CSU, new data supporting tralokinumab for hand AD, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Lynk Pharmaceuticals reveals promising phase 2 trial results for LNK01004, a topical treatment showing efficacy and safety in moderate-to-severe atopic dermatitis.

Dermatology Times is looking back on the top stories in dermatology from the month of November.

Discover the latest trends in aesthetic medicine from ASDS 2025, focusing on safer treatments, improved skin quality, and innovative injectables.

Hair growth, density, and aging patterns differ across populations, influencing the presentation and management of hair disorders like alopecia areata.

Learn more about the in-depth topics covered in the November 2025 print issue of Dermatology Times.

Discover the latest advancements in dermatology from the 2025 Elevate-Derm Fall Conference held in Tampa, Florida.

Dermatology Times is recapping our exclusive expert interviews from the month of November.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of November.

At Elevate-Derm, Shanna Miranti, MPAS, PA-C, and Larissa Schmidt, DPM, outlined how interdisciplinary education, shared therapeutic advances, and evolving career pathways are strengthening the connection between dermatology and podiatry.

Experts reveal how neurotoxins enhance mature skin, emphasizing precision and lower doses for natural, youthful results.

This review of the latest dermatologic studies highlights new research from this week, including immune checkpoint inhibitors in acral melanoma, the link between skin microbiota and asthma, a novel peptide–hyaluronic acid lip serum, and more.

At Elevate-Derm 2025, Lisa Weiss, MMSc, PA-C, outlined the multifactorial approach to CHE, the clinical utility of delgocitinib, and her expanding educational and leadership priorities heading into 2026.

Michael Lewitt, MD, reassures patients that topical ruxolitinib shows minimal systemic absorption despite sharing a mechanism with oral JAK inhibitors.

Discover how Des Fernandes, MB. BCH, FRCS, revolutionized microneedling and regenerative skin care, enhancing results with topical vitamins for optimal skin health.

High-dose topical delgocitinib significantly outperformed oral alitretinoin in reducing HECSI severity at both 12 and 16 weeks.